Cargando…

Correction: Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894829/ https://www.ncbi.nlm.nih.gov/pubmed/33606813 http://dx.doi.org/10.1371/journal.pone.0247690

Ejemplares similares

Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis
por: Diesinger, Torsten, et al.
Publicado: (2020)

Correction: Investigation of Indazole Unbinding Pathways in CYP2E1 by Molecular Dynamics Simulations
por: Shen, Zhonghua, et al.
Publicado: (2012)

Correction: Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
por: Navarro, Victor J., et al.
Publicado: (2019)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Author Correction: Effect of BI-1 on insulin resistance through regulation of CYP2E1
por: Lee, Geum-Hwa, et al.
Publicado: (2018)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Correction: Targeting alkaline ceramidase 3 alleviates the severity of nonalcoholic steatohepatitis by reducing oxidative stress
por: Wang, Kai, et al.
Publicado: (2020)

Correction: Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model
Publicado: (2017)

Author Correction: Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis
por: Waghorn, Philip A., et al.
Publicado: (2021)

Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice
por: Bae, Cho-Rong, et al.
Publicado: (2021)

Correction to: Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan
por: Koda, Masahide, et al.
Publicado: (2018)

Correction: CYP2C9 Genotype vs. Metabolic Phenotype for Individual Drug Dosing—A Correlation Analysis Using Flurbiprofen as Probe Drug
por: Vogl, Silvia, et al.
Publicado: (2015)

Correction: CYP2J3 gene delivery reduces insulin resistance via upregulation of eNOS in fructose-treated rats
por: Xu, Xizhen, et al.
Publicado: (2014)

Gut microbiota and host Cyp450s co-contribute to pharmacokinetic variability in mice with non-alcoholic steatohepatitis: Effects vary from drug to drug
por: Guo, Jing, et al.
Publicado: (2021)

Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease
por: Machado, Mariana Verdelho, et al.
Publicado: (2015)

Correction: Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis
por: Wang, Xingchun, et al.
Publicado: (2022)

Correction to: In vivo imaging of early stages of rheumatoid arthritis by α5β1-integrin-targeted positron emission tomography
por: Notni, Johannes, et al.
Publicado: (2019)

Correction to: CYP79 P450 monooxygenases in gymnosperms: CYP79A118 is associated with the formation of taxiphyllin in Taxus baccata
por: Luck, Katrin, et al.
Publicado: (2017)

Correction to: Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells
por: Zheng, Lufeng, et al.
Publicado: (2019)

Correction to: Mycotic aortic aneurysms post-Intravesical BCG treatment for early-stage bladder carcinoma
por: Wadhwani, Aman, et al.
Publicado: (2019)

Correction to: “Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Correction: Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr (-/-) mice
Publicado: (2019)

Correction to “Severe Hypercalcemia Due to Primary Hyperparathyroidism and Heterozygous Pathogenic Variant of CYP24A1”
Publicado: (2023)

Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice
por: Yang, Jin, et al.
Publicado: (2017)

Evaluating the Influence of Side Stream Cigarette Smoke at an Early Stage of Non-Alcoholic Steatohepatitis Progression in Mice
por: Kim, Jong Won, et al.
Publicado: (2017)

The Apelin Receptor APJ in Hematopoietic Stem Cells/Progenitor Cells in the Early Stage of Non-Alcoholic Steatohepatitis
por: Ando, Wataru, et al.
Publicado: (2017)

Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
por: Zhu, Bo, et al.
Publicado: (2021)

Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
Publicado: (2021)

Correction: Association of CYP2A6*4 with Susceptibility of Lung Cancer: A Meta-Analysis
por: Wang, Lishan
Publicado: (2013)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Cui, Jian, et al.
Publicado: (2019)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Correction: Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities
por: Nuvoli, Barbara, et al.
Publicado: (2023)

Correction: Alcohol-related changes in the intestinal microbiome influence neutrophil infiltration, inflammation and steatosis in early alcoholic hepatitis in mice
por: Lowe, Patrick P., et al.
Publicado: (2017)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
por: Chen, Xiao, et al.
Publicado: (2022)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

Author Correction: Loss of SNORA73 reprograms cellular metabolism and protects against steatohepatitis
por: Sletten, Arthur C., et al.
Publicado: (2021)

Correction: The Schistosoma mansoni Cytochrome P450 (CYP3050A1) Is Essential for Worm Survival and Egg Development
por: Ziniel, Peter D., et al.
Publicado: (2016)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o39tp1tilaehi80g501htv9ffe